IL2 and autoimmune disease: We show that sCTLA-4 is able to decrease the proliferation of T-cells and the production of activator cytokines as IL-2, IL-13 and IFN-γ  in vitro and this regulation may have a clinical feature given that the patients with autoimmune diseases show prominent lymphocyte infiltration and a greater amount of IFN-γ [40].